Kintor Pharma Showcases Positive Phase III Results for Topical AGA Candidate KX-826 at WCHR 2026

Bulletin Express06:23

Kintor Pharmaceutical Limited (Kintor Pharma) announced that data from two studies of its in-house topical androgen receptor inhibitor KX-826 were unveiled at the 14th World Congress for Hair Research (WCHR 2026) in Seoul, held from 28 to 31 May 2026.

The headline presentation covered the final analysis of a China phase III trial evaluating KX-826 1.0 % tincture in adult males with androgenetic alopecia (AGA). Led by Professor Cheng Zhou of Peking University People’s Hospital, the study demonstrated “excellent efficacy and safety” and was selected as an Outstanding Poster by the conference’s scientific committee.

Separately, Professor Leiwei Jiang’s team presented real-world observational data on KX-826 used in combination with topical minoxidil in male AGA patients. The results provide a clinical rationale for a planned phase III trial assessing the combination regimen.

Management stated that the marketing authorization application for KX-826 is moving forward. If approved, KX-826 is positioned to become the first new topical therapeutic class for AGA in roughly 40 years, potentially shifting a treatment landscape long dominated by minoxidil and finasteride.

In line with Rule 18A.08(3) of the Hong Kong Listing Rules, the company cautioned that—apart from its existing 826 topical anti-hair-loss solution and acne cream—there is no guarantee other KX-826 products will reach the market. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106948834?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 06:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106948834","market":"us","top_or_hot":-1,"title":"Kintor Pharma Showcases Positive Phase III Results for Topical AGA Candidate KX-826 at WCHR 2026","media":"Bulletin Express","content":"<p>Kintor Pharmaceutical Limited (Kintor Pharma) announced that data from two studies of its in-house topical androgen receptor inhibitor KX-826 were unveiled at the 14th World Congress for Hair Research (WCHR 2026) in Seoul, held from 28 to 31 May 2026.</p>\n<p>The headline presentation covered the final analysis of a China phase III trial evaluating KX-826 1.0 % tincture in adult males with androgenetic alopecia (AGA). Led by Professor Cheng Zhou of Peking University People’s Hospital, the study demonstrated “excellent efficacy and safety” and was selected as an Outstanding Poster by the conference’s scientific committee.</p>\n<p>Separately, Professor Leiwei Jiang’s team presented real-world observational data on KX-826 used in combination with topical minoxidil in male AGA patients. The results provide a clinical rationale for a planned phase III trial assessing the combination regimen.</p>\n<p>Management stated that the marketing authorization application for KX-826 is moving forward. If approved, KX-826 is positioned to become the first new topical therapeutic class for AGA in roughly 40 years, potentially shifting a treatment landscape long dominated by minoxidil and finasteride.</p>\n<p>In line with Rule 18A.08(3) of the Hong Kong Listing Rules, the company cautioned that—apart from its existing 826 topical anti-hair-loss solution and acne cream—there is no guarantee other KX-826 products will reach the market. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kintor Pharma Showcases Positive Phase III Results for Topical AGA Candidate KX-826 at WCHR 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKintor Pharma Showcases Positive Phase III Results for Topical AGA Candidate KX-826 at WCHR 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-01 06:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kintor Pharmaceutical Limited (Kintor Pharma) announced that data from two studies of its in-house topical androgen receptor inhibitor KX-826 were unveiled at the 14th World Congress for Hair Research (WCHR 2026) in Seoul, held from 28 to 31 May 2026.</p>\n<p>The headline presentation covered the final analysis of a China phase III trial evaluating KX-826 1.0 % tincture in adult males with androgenetic alopecia (AGA). Led by Professor Cheng Zhou of Peking University People’s Hospital, the study demonstrated “excellent efficacy and safety” and was selected as an Outstanding Poster by the conference’s scientific committee.</p>\n<p>Separately, Professor Leiwei Jiang’s team presented real-world observational data on KX-826 used in combination with topical minoxidil in male AGA patients. The results provide a clinical rationale for a planned phase III trial assessing the combination regimen.</p>\n<p>Management stated that the marketing authorization application for KX-826 is moving forward. If approved, KX-826 is positioned to become the first new topical therapeutic class for AGA in roughly 40 years, potentially shifting a treatment landscape long dominated by minoxidil and finasteride.</p>\n<p>In line with Rule 18A.08(3) of the Hong Kong Listing Rules, the company cautioned that—apart from its existing 826 topical anti-hair-loss solution and acne cream—there is no guarantee other KX-826 products will reach the market. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1106948834","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106948834","pubTimestamp":1780266183,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Kintor Pharmaceutical Limited (Kintor Pharma) announced that data from two studies of its in-house topical androgen receptor inhibitor KX-826 were unveiled at the 14th World Congress for Hair...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09939":"开拓药业-B"},"translate_title":"开拓药业在WCHR 2026上展示外用AGA候选药物KX-826的积极III期结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1},"content_text":"Kintor Pharmaceutical Limited (Kintor Pharma) announced that data from two studies of its in-house topical androgen receptor inhibitor KX-826 were unveiled at the 14th World Congress for Hair Research (WCHR 2026) in Seoul, held from 28 to 31 May 2026.\nThe headline presentation covered the final analysis of a China phase III trial evaluating KX-826 1.0 % tincture in adult males with androgenetic alopecia (AGA). Led by Professor Cheng Zhou of Peking University People’s Hospital, the study demonstrated “excellent efficacy and safety” and was selected as an Outstanding Poster by the conference’s scientific committee.\nSeparately, Professor Leiwei Jiang’s team presented real-world observational data on KX-826 used in combination with topical minoxidil in male AGA patients. The results provide a clinical rationale for a planned phase III trial assessing the combination regimen.\nManagement stated that the marketing authorization application for KX-826 is moving forward. If approved, KX-826 is positioned to become the first new topical therapeutic class for AGA in roughly 40 years, potentially shifting a treatment landscape long dominated by minoxidil and finasteride.\nIn line with Rule 18A.08(3) of the Hong Kong Listing Rules, the company cautioned that—apart from its existing 826 topical anti-hair-loss solution and acne cream—there is no guarantee other KX-826 products will reach the market. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106948834","isCrawlerRequest":true}